Market Place
Sourcing Support
All News #Library
Biotech
Nuvation Bio Shares Key Updates
22 Apr 2026 //
PR NEWSWIRE
Eisai, Nuvation Bio Seek Ema Approval For Taletrectinib In Cancer
26 Mar 2026 //
PR NEWSWIRE
Nuvation Bio To Present IBTROZI Data In Ros1+ NSCLC Patients
18 Mar 2026 //
PR NEWSWIRE
Nuvation Bio Launches Global Phase 3 Trial For Safusidenib
09 Feb 2026 //
BUSINESSWIRE
Nuvation Bio To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
BUSINESSWIRE
Nuvation Bio Publishes Positive Phase 2 Results For Safusidenib
03 Dec 2025 //
BUSINESSWIRE
Nuvation Enrolls 1st Patient in Randomized Study of Safusidenib
04 Nov 2025 //
PRESS RELEASE
Nuvation Bio Reveals Q3 2025 Financials And Business Update
03 Nov 2025 //
BUSINESSWIRE
Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib
23 Oct 2025 //
BUSINESSWIRE
Nuvation Bio Initiates First Patient Enrollment In Ibtrozi
30 Sep 2025 //
BUSINESSWIRE
Nuvation Bio Gets Japan Nod for IBTROZITM in Advanced ROS1+ NSCLC
19 Sep 2025 //
BUSINESSWIRE
Nuvation Announces Data from Pivotal Clinical Studies of Ibtrozi
07 Sep 2025 //
BUSINESSWIRE
Nuvation Bio to Participate in Upcoming Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Nuvation Bio to Report Second Quarter 2025 Financial Results
24 Jul 2025 //
BUSINESSWIRE
Taletrectinib Added to NCCN Guidelines for ROS1+ NSCLC Cancer
24 Jun 2025 //
BUSINESSWIRE
Nuvation Bio to Present New Data on Taletrectinib at ASCO 2025
21 May 2025 //
BUSINESSWIRE
Nuvation Bio to Present Data for Taletrectinib vs. Entrectinib
13 May 2025 //
BUSINESSWIRE
Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
07 Oct 2024 //
BUSINESSWIRE
Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data
14 Sep 2024 //
ENDPNTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.